PPARG and schizophrenia: Moreover, the PPAR-γ ligand 15-delta_prostaglandin_J2 was present as an astrocyte-, BD- and schizophrenia-modifying agent (Table 1a–c), further emphasising the potential importance of PPAR-γ in reactive astrogliosis and as a therapeutic target in neurodegenerative diseases56–58.